期刊文献+

High-grade gliomas: reality and hopes 被引量:6

High-grade gliomas: reality and hopes
在线阅读 下载PDF
导出
摘要 In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, the progress has been impressive. For example, discoveries at the molecular level have already impacted imaging, surgery, radiotherapy, and systemic therapies, and they are expected to play an increasing role in the management of these cancers. The European Organization for Research and Treatment of Cancer(EORTC) has pioneered new treatment strategies and contributed to new standards. The articles in this issue will cover basic molecular biological principles applicable today, novel surgical approaches, innovations in radiotherapy planning and delivery, evidence-based standards for radiotherapy alone or combined with chemotherapy, current standards and novel approaches for systemic treatments, and the important but often neglected field of health-related quality of life. Despite the advances described in these articles, the overall prognosis of high-grade glioma, especially glioblastoma, remains poor, and more research is needed to address this problem. In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, the progress has been impressive. For example, discoveries at the molecular level have already impacted imaging, surgery, radiotherapy, and systemic therapies, and they are expected to play an increasing role in the management of these cancers. The European Organization for Research and Treatment of Cancer (EORTC) has pioneered new treatment strategies and contributed to new standards. The articles in this issue will cover basic molecular biological principles applicable today, novel surgical approaches, innovations in radiotherapy planning and delivery, evidence-based standards for radiotherapy alone or combined with chemotherapy, current standards and novel approaches for systemic treatments, and the important but often neglected field of health-related quality of life. Despite the advances described in these articles, the overall prognosis of high-grade glioma, especially glioblastoma, remains poor, and more research is needed to address this problem.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 2014年第1期1-3,共3页
关键词 胶质瘤 全身治疗 分子水平 手术方法 生物学原理 发展趋势 放射治疗 标准 High-grade glioma, glioblastoma multiforme, surgery, radiotherapy, chemotherapy, health-related quality of life
  • 相关文献

参考文献6

二级参考文献216

  • 1Paravati A J, Heron DE, Landsittel D, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group- Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol, 2011,104:339-349.
  • 2Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol, 2006,24:2563-2569.
  • 3Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 2013,113:259-266.
  • 4Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007.114:97-109.
  • 5Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol, 2013,31:337-343.
  • 6van den Bent M J, Brandes AA, Taphoorn M J, et al. Adjuvant procarbazine, Iomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendrogtioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol, 2013,31:344- 350.
  • 7Weller M, Stupp R, Hegi M, et al. Personalized care in neuro- oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Qncol, 2012,14 Suppl 4:iv100-108.
  • 8Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. ClinicalTrials.gov Identifier:NCT00626990. Verified May 2011 by National Cancer Institute (NCl). ClinicalTrials. gov processed this record on December 01, 2013. http:// clinicaltrials.gov/ct2/show/NCT00626990?term= NCT00626990&ra nk=l.
  • 9Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. ClinicalTrials.gov identifier: NCT00887146, Verified November 2013 by Alliance for Clinical Trials in Oncology. ClinicalTrials.gov processed this record on December 01, 2013. http://clinicaltrials.gov/ct2/show/NCTO0887146 ?term=NCTOO887146.&rank= 1.
  • 10Hofer S, Lassman AB. Molecular markers in gliomas: impact for the clinician. Targ Oncol, 2010,5:201-210.

共引文献39

同被引文献23

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部